



RON CHAPMAN, MD, MPH  
Director

State of California—Health and Human Services Agency  
California Department of Public Health




EDMUND G. BROWN JR.  
Governor

November 23, 2011

IZB-FY-1112-05

TO: Vaccines for Children (VFC) Providers

FROM: John Talarico, D.O., M.P.H., Chief   
Center for Infectious Diseases  
Division of Communicable Disease Control, Immunization Branch

Subject: Expanded Indications for MCV4 include High-Risk Children

## Summary

In addition to a routine dose at 11-12 years old and a booster dose for adolescents at age 16 years, ACIP now also recommends meningococcal conjugate vaccine (MCV4) for high-risk children as young as 9 months of age.

### New: MCV4 for High-Risk Children as Young as Age 9 months

In October 2011, ACIP provided expanded recommendations for the use of quadrivalent meningococcal conjugate vaccine (MCV4) in children as young as 9 months of age who are at increased risk of developing meningococcal disease.

Children 9 months-23 months of age with the following risks should receive a primary series of **2 doses of MCV4, 3 months apart:**

- Those with persistent complement component deficiencies
- Traveling to or residing in countries where meningococcal disease is hyperendemic or epidemic
- In a defined risk group during a community or institutional meningococcal outbreak

Children 2- 10 years of age with the following risks should receive a primary series of **2 doses of MCV4, 2 months apart:**

- Functional or anatomic asplenia
- Persistent complement component deficiencies and no prior doses of MCV4
- At increased risk of meningococcal disease and infected with HIV

Children 2-10 years of age not previously immunized with MCV4 and with the following risks should receive 1 dose of MCV4:

- Traveling to or reside in countries where meningococcal disease is hyperendemic or epidemic;
- In a defined risk group during a community or institutional meningococcal outbreak.

#### **Reminder: ACIP recommends a booster dose of MCV4 for Older Adolescents**

<u>Age in years at first dose of MCV4</u>	<u>Age in years for booster dose</u>
11 or 12	16
13 through 15	16 through 18
≥16	No booster dose needed.

#### **Current FDA License Age Indications for MCV4**

- Menactra<sup>®</sup> (sanofi pasteur) -- 9 months through 55 years of age.
- Menveo<sup>®</sup> (Novartis Vaccines and Diagnostics, Inc.) -- 2 through 55 years of age.

#### **Vaccine Information Statement (VIS)**

The updated MCV4 vaccine information statement, with new information on contraindications, precautions and adverse events, can be downloaded at [www.EZIZ.org](http://www.EZIZ.org).

#### **ACIP Recommendations on MCV4**

Providers are encouraged to review the details of ACIP recommendations for MCV4:

- Use in children as young as 9 months - October 2011  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm>
- Use in high-risk children age 2 through 10 years; updated booster guidance - August 2011 <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm>
- Adolescent booster dose - January 2011  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm>
- Revaccination of persons at prolonged increased risk for meningococcal disease - September 2009  
[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s\\_cid=mm5837a4\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s_cid=mm5837a4_e)

#### **Questions?**

If you have any questions, please call your VFC Field Representative or the VFC Program at 877-243-8832 (877-2GET-VFC) or visit [www.EZIZ.org](http://www.EZIZ.org).

cc: CDPH Immunization Branch Field Representatives  
Local Health Officers  
Local Health Department Immunization Coordinators  
Local Health Department CHDP Program Directors  
Jane Ogle, Acting Chief, Medi-Cal Managed Care Division, DHCS  
Shabbir Ahmad, D.V.M., M.S., Ph.D., Acting Chief, Maternal, Child and Adolescent Health Program,  
CDPH  
Laurie Weaver, Chief, Office of Family Planning, CDPH  
Shelley Rouillard, Deputy Director, Benefits and Quality Monitoring Division, MRMIB  
Emmee Nguyen, Benefits and Quality Monitoring, MRMIB  
Jill Young, Benefits and Quality Monitoring, MRMIB  
Sherie Smalley, M.D., Chief, Medi-Cal Policy and Benefits Branch, Medi-Cal  
Benefits, Waiver Analysis and Rates Division, DHCS  
Steve Shih, M.D. Medical Policy Section, Medi-Cal Benefits, Waiver Analysis and Rates  
Division, DHCS  
Alan Morita, Pharm.D., Medi-Cal Pharmacy Policy Branch, DHCS  
Robert Dimand, M.D., Chief, Children Medical Services Branch, DHCS  
Jill Abramson, M.D., M.P.H., Children Medical Services Branch, DHCS